The association between cancer and PH: A tale of two diseases

4 May 2022

A PVRI 2022 Digital webinar

Presentations

  • Cancer induced PH: Embolism as a major inducer, Timothy Morris
  • Cancer induced PH: Microenvironmental cancer niche as a major inducer, Rajkumar Savai 
  • Cancer therapies induced PH, Frédéric Perros
  • Cancer related signalling mechanisms underlying PH development, Olivier Boucherat 
  • FOXO3: A new potential therapeutic target in pulmonary arterial hypertension, Yann Grobs
  • Non-invasive surrogate markers of PH are associated with poor survival in lung cancer patients, Michael Cekay

Poll

Start of webinar poll

1. N/A

 

2. Talk 2: PH impacts the lung cancer prognosis and survival

Agree - 100%

Disagree - 0%

 

3. Talk 3: Current animal models of pulmonary hypertension, acute and hyperproliferative in nature, do not predict the effect of anti-cancer therapies in the setting

Yes - 100%

No - 0%

 

4. Talk 4: Should we focus on signaling pathways identified in cancer to find new actionable targets in PAH?

Yes - 100%

No - 0%

 

5. Talk 5: TFP is an antagonist of calmodulin and has a cardioprotective effect on left ventricle. In PAH, do you think TFP treatment could improve hemodynamic parameters by playing a role on lung and right ventricle maladaptive remodeling?

Yes - 75%

No - 25%

 

Talk 6: Lung cancer patients with pulmonary hypertension may profit from guidelines based pulmonary hypertension therapy.

Agree - 75%

Disagree - 25%

Speakers & Moderators

Timothy Morris, University of California San Diego, USA
Rajkumar Savai, Justus Liebig University Giessen, Germany
Frédéric Perros, The Inserm U999, France
Olivier Boucherat, University Institute of Cardiology and Pneumology of Quebec, Canada
Yann Grobs, Laval University, Canada
Michael Cekay, Justus Liebig University Giessen, Germany
Share:
Additional comments are available to members. Login or register to become a member today